{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:00:59Z","timestamp":1774267259888,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T00:00:00Z","timestamp":1445817600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-1205-4","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T22:08:48Z","timestamp":1445897328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study"],"prefix":"10.1186","volume":"15","author":[{"given":"AH","family":"van\u2019t Hoog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bergval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tukvadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sengstake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Aspindzelashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RM","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cobelens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,26]]},"reference":[{"key":"1205_CR1","volume-title":"Global Tuberculosis Report 2013","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Global Tuberculosis Report 2013. Geneva: World Health Organization (WHO\/HTM\/TB\/2013.11); 2013."},{"key":"1205_CR2","unstructured":"World Health Organization. Revised definitions and reporting framework for tuberculosis - 2013 revision. Geneva: World Health Organization (WHO\/HTM\/TB\/2013.2); 2013."},{"issue":"2","key":"1205_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5588\/ijtld.13.0468","volume":"18","author":"N Tukvadze","year":"2014","unstructured":"Tukvadze N, Bablishvili N, Apsindzelashvili R, Blumberg HM, Kempker RR. Performance of the MTBDRsl assay in Georgia. Int J Tuberc Lung Dis. 2014;18(2):233\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"1205_CR4","doi-asserted-by":"publisher","first-page":"e31563","DOI":"10.1371\/journal.pone.0031563","volume":"7","author":"N Tukvadze","year":"2012","unstructured":"Tukvadze N, Kempker RR, Kalandadze I, Kurbatova E, Leonard MK, Apsindzelashvili R, et al. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One. 2012;7(2):e31563.","journal-title":"PLoS One"},{"key":"1205_CR5","doi-asserted-by":"crossref","unstructured":"Barnard M, Warren R, Gey Van Pittius N, van Helden P, Bosman M, Streicher E, et al. Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. Am J Respir Crit Care Med. 2012;186(12):1298\u2013305.","DOI":"10.1164\/rccm.201205-0960OC"},{"key":"1205_CR6","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva: World Health Organization (WHO\/HTM\/TB\/2011.6); 2011."},{"issue":"8","key":"1205_CR7","doi-asserted-by":"publisher","first-page":"e23081","DOI":"10.1371\/journal.pone.0023081","volume":"6","author":"M Bonnet","year":"2011","unstructured":"Bonnet M, Pardini M, Meacci F, Orru G, Yesilkaya H, Jarosz T, et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS One. 2011;6(8):e23081.","journal-title":"PLoS One"},{"issue":"8","key":"1205_CR8","doi-asserted-by":"publisher","first-page":"e43240","DOI":"10.1371\/journal.pone.0043240","volume":"7","author":"I Bergval","year":"2012","unstructured":"Bergval I, Sengstake S, Brankova N, Levterova V, Abadia E, Tadumaze N, et al. Combined species identification, genotyping, and drug resistance detection of Mycobacterium tuberculosis cultures by MLPA on a bead-based array. 1. PLoS One. 2012;7(8):e43240.","journal-title":"PLoS One"},{"key":"1205_CR9","first-page":"CD010705","volume":"10","author":"G Theron","year":"2014","unstructured":"Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, et al. The diagnostic accuracy of the GenoType((R)) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Cochrane Database Syst Rev. 2014;10:CD010705.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1205_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.7326\/0003-4819-126-1-199701010-00026","volume":"126","author":"AJ Saah","year":"1997","unstructured":"Saah AJ, Hoover DR. \u201cSensitivity\u201d and \u201cspecificity\u201d reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Intern Med. 1997;126(1):91\u20134.","journal-title":"Ann Intern Med"},{"key":"1205_CR11","volume-title":"Tuberculosis surveillance and monitorin in Europe 2013","author":"European Centre for Disease Prevention and Control\/WHO RegionalOffice for Europe","year":"2014","unstructured":"European Centre for Disease Prevention and Control\/WHO RegionalOffice for Europe. Tuberculosis surveillance and monitorin in Europe 2013. Stockholm: European Centre for Disease Prevention and Control; 2014."},{"issue":"4","key":"1205_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.tube.2009.04.002","volume":"89","author":"M Pardini","year":"2009","unstructured":"Pardini M, Niemann S, Varaine F, Iona E, Meacci F, Orru G, et al. Characteristics of drug-resistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe. Tuberculosis (Edinb). 2009;89(4):317\u201324.","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"1205_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa0800106","volume":"359","author":"CD Mitnick","year":"2008","unstructured":"Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359(6):563\u201374.","journal-title":"N Engl J Med"},{"issue":"16","key":"1205_CR14","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367(16):1508\u201318.","journal-title":"N Engl J Med"},{"issue":"9","key":"1205_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7326\/0003-4819-144-9-200605020-00008","volume":"144","author":"TH Holtz","year":"2006","unstructured":"Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650\u20139.","journal-title":"Ann Intern Med"},{"key":"1205_CR16","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis, Emergency update, 2008","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, Emergency update, 2008. Geneva: World Health Organization; 2008."},{"issue":"2","key":"1205_CR17","doi-asserted-by":"publisher","first-page":"e56074","DOI":"10.1371\/journal.pone.0056074","volume":"8","author":"C Lu","year":"2013","unstructured":"Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS One. 2013;8(2):e56074.","journal-title":"PLoS One"},{"issue":"11","key":"1205_CR18","doi-asserted-by":"publisher","first-page":"e1001120","DOI":"10.1371\/journal.pmed.1001120","volume":"8","author":"A Vassall","year":"2011","unstructured":"Vassall A, van Kampen S, Sohn H, Michael JS, John K, den Boon S, et al. Rapid diagnosis of tuberculosis with the Xpert MTB\/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2011;8(11):e1001120.","journal-title":"PLoS Med"},{"issue":"43","key":"1205_CR19","doi-asserted-by":"publisher","first-page":"15520","DOI":"10.1073\/pnas.1404386111","volume":"111","author":"GM Knight","year":"2014","unstructured":"Knight GM, Griffiths UK, Sumner T, Laurence YV, Gheorghe A, Vassall A, et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014;111(43):15520\u20135. Supplement page 48.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1205_CR20","doi-asserted-by":"crossref","unstructured":"Gunther G, Gomez GB, Lange C, Rupert S, van Leth F. Availability, price and affordability of anti-tuberculosis drugs in Europe: A TBNET survey. Eur Respir J. 2014;13.","DOI":"10.1183\/09031936.00124614"},{"issue":"1","key":"1205_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/11595340-000000000-00000","volume":"30","author":"C Fitzpatrick","year":"2012","unstructured":"Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30(1):63\u201380.","journal-title":"Pharmacoeconomics"},{"key":"1205_CR22","unstructured":"The World Bank. GDP deflator. 2014. 23-4-0014. 2014. http:\/\/data.worldbank.org\/indicator\/NY.GDP.DEFL.ZS . Date accessed: 23-04-2014."},{"issue":"3","key":"1205_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1128\/JCM.02701-13","volume":"52","author":"TC Rodwell","year":"2014","unstructured":"Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, et al. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol. 2014;52(3):781\u20139.","journal-title":"J Clin Microbiol"},{"key":"1205_CR24","unstructured":"World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization (WHO\/HTM\/TB\/2014.11); 2014."},{"issue":"1","key":"1205_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1086\/653115","volume":"51","author":"KR Jacobson","year":"2010","unstructured":"Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51(1):6\u201314.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1205_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00134712","volume":"42","author":"D Falzon","year":"2013","unstructured":"Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42(1):156\u201368.","journal-title":"Eur Respir J"},{"issue":"6","key":"1205_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.5588\/ijtld.13.0776","volume":"18","author":"DW Dowdy","year":"2014","unstructured":"Dowdy DW, van\u2019t Hoog A, Shah M, Cobelens F. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis. Int J Tuberc Lung Dis. 2014;18(6):647\u201354.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1205_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2334-9-67","volume":"9","author":"F Bwanga","year":"2009","unstructured":"Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis. 2009;9:67.","journal-title":"BMC Infect Dis"},{"key":"1205_CR29","volume-title":"Tuberculosis surveillance and monitorin in Europe 2011","author":"European Centre for Disease Prevention and Control\/WHO RegionalOffice for Europe","year":"2012","unstructured":"European Centre for Disease Prevention and Control\/WHO RegionalOffice for Europe. Tuberculosis surveillance and monitorin in Europe 2011. Stockholm: European Centre for Disease Prevention and Control; 2012."},{"key":"1205_CR30","first-page":"CD009593","volume":"1","author":"KR Steingart","year":"2014","unstructured":"Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert(R) MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (updated). Cochrane Database Syst Rev. 2014;1:CD009593.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"1205_CR31","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.5588\/ijtld.12.0773","volume":"17","author":"AL Hertog den","year":"2013","unstructured":"den Hertog AL, Daher S, Straetemans M, Scholing M, Anthony RM. No added value of performing Ziehl-Neelsen on auramine-positive samples for tuberculosis diagnostics. Int J Tuberc Lung Dis. 2013;17(8):1094\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"1205_CR32","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5588\/ijtld.12.0395","volume":"17","author":"AS Rabin","year":"2013","unstructured":"Rabin AS, Kuchukhidze G, Sanikidze E, Kempker RR, Blumberg HM. Prescribed and self-medication use increase delays in diagnosis of tuberculosis in the country of Georgia. Int J Tuberc Lung Dis. 2013;17(2):214\u201320.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9670","key":"1205_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","volume":"373","author":"MB Conde","year":"2009","unstructured":"Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009;373(9670):1183\u20139.","journal-title":"Lancet"},{"issue":"5","key":"1205_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0962-8479(94)90079-5","volume":"75","author":"LJ Gonzalez-Montaner","year":"1994","unstructured":"Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin, Rifabutin Study Group. Tuber Lung Dis. 1994;75(5):341\u20137.","journal-title":"Tuber Lung Dis"},{"issue":"4","key":"1205_CR35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/jac\/dkm025","volume":"59","author":"J Fortun","year":"2007","unstructured":"Fortun J, Martin-Davila P, Molina A, Navas E, Hermida JM, Cobo J, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother. 2007;59(4):794\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1205_CR36","volume-title":"Global Tuberculosis Control: WHO Report 2012","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. Global Tuberculosis Control: WHO Report 2012. Geneva: World Health Organization (WHO\/HTM\/TB\/2012.6); 2012."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-1205-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:17:38Z","timestamp":1567297058000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-1205-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,26]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-1205-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,26]]},"article-number":"473"}}